Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Living Cell Technologies ( (AU:1AI) ) has provided an update.
Algorae Pharmaceuticals Limited has applied for quotation on the ASX of 44,241,067 new fully paid ordinary shares under its ticker 1AI. The new securities, issued on March 27, 2026, expand the company’s quoted share capital and may enhance its market liquidity and access to equity funding, with potential implications for existing shareholders and future capital-raising activities.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australian-listed biopharmaceutical company, trading under the ASX code 1AI. The company operates in the pharmaceuticals sector, focusing on the development and commercialisation of drug products and related technologies for healthcare markets.
YTD Price Performance: 21.43%
Average Trading Volume: 1,504,027
Technical Sentiment Signal: Hold
Current Market Cap: A$29.19M
See more insights into 1AI stock on TipRanks’ Stock Analysis page.